The primary trial intends to recruit approximately 1800 participants and will conclude in February 2026
9 Conclusion Growing research indicates that PD is more than simply a brain issue
Bruzzese L, Rostain J-C, Ne L, Condo J, Mottola G, Adjriou N, Mercier L, Berge-Lefranc J-L, Fromonot J, Kipson N, Lucciano M, Durand-Gorde J-M, Jammes Y, Guieu R, Ruf J, Fenouillet E
Highlights Sodium-glucose cotransporter-2 inhibitors (SGLT2-i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) provide modest but clinically meaningful blood pressure (BP) lowering effects in people with hypertension and cardiometabolic comorbidities
This can include increased wheezing, shortness of breath, and chest tightness
blog.telewellnessmd.com+1Hudson Weekly+1 Benefits for Gut Health 1